Moreover, resistance to lapatinib and nilotinib treatment alone was associated with KRAS mutation phenotype in both COREAD and Pan-Cancer (Excel sheet, sub-sheet 3.5), emphasizing the value of combinatorial regime against KRAS mutant tumors. The gene discussed is KRAS; the disease is cancer.